Inorganic phosphate (Pi) is a crucial electrolyte for maintaining homeostasis. Most methods measure Pi using ammonium phosphomolybdate under highly acidic conditions. Phospholipid-rich substances, such as liposomal amphotericin B, have been previously reported to artificially elevate Pi levels due to phospholipid hydrolysis in the acidic medium. This study aimed to investigate whether endogenous lipoproteins interfere with Pi measurement in cases of hyperlipidemia.
Methods
We conducted a retrospective study comparing mean Pi levels in 194,636 patients divided in groups with varying degrees of lipemia. Additionally, we performed a prospective study involving 85 patients presenting a range of lipemia to evaluate changes in Pi levels before and after plasma high-speed centrifugation-filtration, which retains all endogenous lipoproteins.
Results
The retrospective study revealed a significant increase in Pi levels in relation with the degree of lipemia (P < .0001). The prospective study demonstrated a significant decrease in phosphatemia (P < .0001), with mean Pi levels of 1.36 mmol/L (4.22 mg/dL) before filtration and 1.27 mmol/L (3.94 mg/dL) after filtration, representing a mean decrease of 6.8%. Furthermore, the bias, defined as 100*(([Pi]before – [Pi]after)/[Pi]before), was correlated with the lipemia level (r = 0.34, P = .001).
Conclusions
This study confirms that hyperlipidemia induces an analytically significant pseudohyperphosphatemia in a lipemia-dependent manner.
CrookMSwaminathanR. Disorders of plasma phosphate and indications for its measurement. Ann Clin Biochem1996; 33 ( Pt 5)(5): 376–396.
3.
PeacockM. Phosphate metabolism in health and disease. Calcif Tissue Int2021; 108(1): 3–15.
4.
HortonSFlemingKAKutiM, et al.The top 25 laboratory tests by volume and revenue in five different countries. Am J Clin Pathol2019; 151(5): 446–451.
5.
TaylorAEMillerCW. On the estimation of phosphorus in biological material. J Biol Chem1914; 18(2): 215–224.
6.
BellRDDoisyEA. Rapid colorimetric methods for the determination of phosphorus in urine and blood. J Biol Chem1920; 44(1): 55–67.
7.
SimonsenDGWertmanMWestoverLM, et al.The determination of serum phosphate by the molybdivanadate method. J Biol Chem1946; 166(2): 747–755.
8.
TausskyHHShorrEKurzmannG. A Microcolorimetric method for the determination of inorganic phosphorus. J Biol Chem1953; 202(2): 675–685.
9.
FiskeCHSubbarowY. The colorimetric determination of phosphorus. J Biol Chem1925; 66(2): 375–400.
10.
DalyJAErtingshausenG. Direct method for determining inorganic phosphate in serum with the ‘CentrifiChem. Clin Chem1972; 18(3): 263–265.
11.
LaneJWRehakNNHortinGL, et al.Pseudohyperphosphatemia associated with high-dose liposomal amphotericin B therapy. Clin Chim Acta2008; 387(1–2): 145–149.
12.
JensenGMBunchTHWolfS, et al.Erroneous determination of hyperphosphatemia (‘pseudohyperphosphatemia’) in sera of patients that have been treated with liposomal amphotericin B (AmBisome). Clin Chim Acta2010; 411(23–24): 1900–1905.
13.
SandbergSCoskunACarobeneA, et al.Analytical performance specifications based on biological variation data – considerations, strengths and limitations. Clin Chem Lab Med2024; 62(8): 1483–1489.
14.
AarsandAFernandez-CallePWebsterC, et al.The EFLM biological variation database. Available from: https://biologicalvariation.eu/
15.
ThongprayoonCCheungpasitpornWMaoMA, et al.Admission hyperphosphatemia increases the risk of acute kidney injury in hospitalized patients. J Nephrol2018; 31(2): 241–247.
16.
ManghatPSodiRSwaminathanR. Phosphate homeostasis and disorders. Ann Clin Biochem2014; 51(6): 631–656.
17.
LeafDEWolfM. A physiologic–based approach to the evaluation of a patient with hyperphosphatemia. Am J Kidney Dis2013; 61(2): 330–336.
18.
O’NeillWC. The fallacy of the calcium-phosphorus product. Kidney Int2007; 72(7): 792–796.
19.
KoseogluMHurAAtayA, et al.Effects of hemolysis interferences on routine biochemistry parameters. Biochem Med2011; 21(1): 79–85.
20.
MolinarisVBianchettiMGMilaniGP, et al.Interferences in the measurement of circulating phosphate: a literature review. Clin Chem Lab Med2020; 58(12): 1971–1977.
21.
McClureDLaiLCCornellC. Pseudohyperphosphataemia in patients with multiple myeloma. J Clin Pathol1992; 45(8): 731–732.
22.
MaysJAGreeneDNPoonA, et al.Pseudohypophosphatemia associated with high-dose liposomal amphotericin B therapy. Clin Biochem2017; 50(16): 967–971.
23.
SuchinEJCizmanBConnollyBR, et al.Pseudohyperphosphatemia in a hyperphosphatemic hemodialysis patient. Am J Kidney Dis2002; 40(5): E18.
24.
CachatFBardyDDurusselC, et al.Spurious hyperphosphatemia in a patient with alteplase-locked central venous catheter. Pediatr Nephrol2006; 21(2): 301–302.
25.
GoundenVZhaoZ. Eltrombopag interference in routine chemistry testing. Ann Clin Biochem2016; 53(5): 611–614.
FérézouJGulikADomingoN, et al.Intralipid 10%: physicochemical characterization. Nutrition2001; 17(11–12): 930.
31.
Fernández-PrendesCCastro-CastroMJJiménez-AñónL, et al.Discrepancies in lipemia interference between endogenous lipemic samples and smoflipid®-supplemented samples. EJIFCC2023; 34(1): 27–41.
32.
NikolacNSimundicAMMiksaM, et al.Heterogeneity of manufacturers’ declarations for lipemia interference — an urgent call for standardization. Clin Chim Acta2013; 426: 33–40.
33.
KrollMH. Evaluating interference caused by lipemia. Clin Chem2004; 50(11): 1968–1969.
34.
RodwellVWBenderDBothamKM, et al.Harper’s illustrated biochemistry. McGraw Hill Professional, 2018, p. 800.
35.
DashtiMKulikWHoekF, et al.A phospholipidomic analysis of all defined human plasma lipoproteins. Sci Rep2011; 1(1): 139.
SoleimaniNMohammadzadehSAsadianF. Lipemia interferences in biochemical tests, investigating the efficacy of different removal methods in comparison with ultracentrifugation as the gold standard. J Anal Methods Chem2020; 2020: 9857636.
38.
WoodPImaichiKKnowlesJ, et al.The lipid composition of human plasma chylomicrons. J Lipid Res1964; 5: 225–231.
39.
VanceJEVanceDE. Specific pools of phospholipids are used for lipoprotein secretion by cultured rat hepatocytes. J Biol Chem1986; 261(10): 4486–4491.
40.
Fernández-GarcíaRde PabloEBallesterosMP, et al.Unmet clinical needs in the treatment of systemic fungal infections: the role of amphotericin B and drug targeting. Int J Pharm2017; 525(1): 139–148.
41.
JiJZMengQH. Evaluation of the interference of hemoglobin, bilirubin, and lipids on Roche Cobas 6000 assays. Clin Chim Acta2011; 412(17–18): 1550–1553.
